Trial SWOG-S2104


Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Syma Iqbal, M.D.
Other Trial Staff:  Fahim Raian, D.M., Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Mary Ordaz, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Niranjan Bhatt, D.M., Rabia Rehman, Coordinator, Diane Chun, Coordinator, Eva Ritzmann, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.